药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Difenoxin
Risankizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Risankizumab.
Difenoxin
Cemiplimab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Cemiplimab.
Difenoxin
Lanadelumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Lanadelumab.
Difenoxin
Lecanemab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Lecanemab.
Difenoxin
Fanolesomab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Fanolesomab.
Difenoxin
Galcanezumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Galcanezumab.
Difenoxin
Fremanezumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Fremanezumab.
Difenoxin
Eptinezumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Eptinezumab.
Difenoxin
Erenumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Erenumab.
Difenoxin
Burosumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Burosumab.
Difenoxin
Tildrakizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tildrakizumab.
Difenoxin
Besilesomab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Besilesomab.
Difenoxin
Sulesomab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Sulesomab.
Difenoxin
Emicizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Emicizumab.
Difenoxin
Human cytomegalovirus immune globulin
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Human cytomegalovirus immune globulin.
Difenoxin
Nebacumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Nebacumab.
Difenoxin
Edrecolomab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Edrecolomab.
Difenoxin
Bezlotoxumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Bezlotoxumab.
Difenoxin
Olokizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Olokizumab.
Difenoxin
Tregalizumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Tregalizumab.